{"id":53494,"date":"2023-01-31T23:02:40","date_gmt":"2023-01-31T22:02:40","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/an2-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/"},"modified":"2023-01-31T23:02:40","modified_gmt":"2023-01-31T22:02:40","slug":"an2-therapeutics-to-present-at-svb-securities-global-biopharma-conference","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/an2-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/","title":{"rendered":"AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference"},"content":{"rendered":"<div>\n<p>MENLO PARK, Calif.&#8211;(BUSINESS WIRE)&#8211;AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, Co-Founder, President and CEO will present at the SVB Securities Global Biopharma Conference.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230131005415\/en\/1694868\/5\/an2_therapeutics_logo_weba_%28003%29.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230131005415\/en\/1694868\/21\/an2_therapeutics_logo_weba_%28003%29.jpg\"><\/a><\/p>\n<p>\nDetails of the event is as follows:\n<\/p>\n<p>\nSVB Securities Global Biopharma Conference, February 14-15, 2023 (virtual)\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nEric Easom, Co-Founder, President and CEO will present a corporate overview on Tuesday, February 14 at 5:00 p.m. ET.\n<\/li>\n<\/ul>\n<p>\nA webcast of the presentation can be accessed on the Investors section of the AN2 Therapeutics website at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.an2therapeutics.com&amp;esheet=53294166&amp;newsitemid=20230131005415&amp;lan=en-US&amp;anchor=www.an2therapeutics.com&amp;index=1&amp;md5=2ed831609b05aa891a77a7eb1ca8f76f\" rel=\"nofollow noopener\" shape=\"rect\">www.an2therapeutics.com<\/a>. An archived replay will be available for at least 30 days following the presentation.\n<\/p>\n<p>\n<b>About AN2 Therapeutics, Inc.<\/b>\n<\/p>\n<p>\nAN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Our lead candidate is epetraborole, which we are studying in a pivotal Phase 2\/3 trial as a once-daily, oral treatment with a novel mechanism of action for patients with NTM lung disease, a rare, chronic, and progressive infectious disease caused by bacteria, known as mycobacteria, that leads to irreversible lung damage and can be fatal. For more information, please visit our website at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.an2therapeutics.com&amp;esheet=53294166&amp;newsitemid=20230131005415&amp;lan=en-US&amp;anchor=www.an2therapeutics.com&amp;index=2&amp;md5=c23f6995e1a6054d31126c2617803eaa\" rel=\"nofollow noopener\" shape=\"rect\">www.an2therapeutics.com<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>COMPANY CONTACT:<\/b><br \/>Lucy O. Day<br \/>\n<br \/>Chief Financial Officer<br \/>\n<br \/><a target=\"_blank\" href=\"mailto&#58;&#108;&#46;&#100;&#97;&#121;&#64;&#x61;&#x6e;&#x32;&#x74;&#x68;&#x65;&#x72;&#x61;&#x70;&#x65;&#x75;&#x74;ics&#46;co&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x6c;&#x2e;&#100;&#97;&#121;&#64;&#x61;&#x6e;&#x32;&#116;&#104;er&#x61;&#x70;&#x65;&#117;&#116;i&#x63;&#x73;&#x2e;&#99;&#111;&#109;<\/a>\n<\/p>\n<p>\n<b>INVESTOR AND MEDIA CONTACT:<\/b><br \/>Anne Bowdidge<br \/>\n<br \/><a target=\"_blank\" href=\"mailto:ir&#64;an2therapeutic&#115;&#46;&#99;&#111;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x69;&#x72;&#64;&#97;&#110;2&#x74;&#x68;&#x65;&#114;&#97;pe&#x75;&#x74;&#x69;&#99;&#115;&#46;&#x63;&#x6f;&#x6d;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>MENLO PARK, Calif.&#8211;(BUSINESS WIRE)&#8211;AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, Co-Founder, President and CEO will present at the SVB Securities Global Biopharma Conference. Details of the event is as follows: SVB Securities Global &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/an2-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53494","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/an2-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MENLO PARK, Calif.&#8211;(BUSINESS WIRE)&#8211;AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, Co-Founder, President and CEO will present at the SVB Securities Global Biopharma Conference. Details of the event is as follows: SVB Securities Global ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/an2-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-31T22:02:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230131005415\/en\/1694868\/21\/an2_therapeutics_logo_weba_%28003%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/an2-therapeutics-to-present-at-svb-securities-global-biopharma-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/an2-therapeutics-to-present-at-svb-securities-global-biopharma-conference\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference\",\"datePublished\":\"2023-01-31T22:02:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/an2-therapeutics-to-present-at-svb-securities-global-biopharma-conference\\\/\"},\"wordCount\":241,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/an2-therapeutics-to-present-at-svb-securities-global-biopharma-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230131005415\\\/en\\\/1694868\\\/21\\\/an2_therapeutics_logo_weba_%28003%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/an2-therapeutics-to-present-at-svb-securities-global-biopharma-conference\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/an2-therapeutics-to-present-at-svb-securities-global-biopharma-conference\\\/\",\"name\":\"AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/an2-therapeutics-to-present-at-svb-securities-global-biopharma-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/an2-therapeutics-to-present-at-svb-securities-global-biopharma-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230131005415\\\/en\\\/1694868\\\/21\\\/an2_therapeutics_logo_weba_%28003%29.jpg\",\"datePublished\":\"2023-01-31T22:02:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/an2-therapeutics-to-present-at-svb-securities-global-biopharma-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/an2-therapeutics-to-present-at-svb-securities-global-biopharma-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/an2-therapeutics-to-present-at-svb-securities-global-biopharma-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230131005415\\\/en\\\/1694868\\\/21\\\/an2_therapeutics_logo_weba_%28003%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230131005415\\\/en\\\/1694868\\\/21\\\/an2_therapeutics_logo_weba_%28003%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/an2-therapeutics-to-present-at-svb-securities-global-biopharma-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/an2-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/","og_locale":"en_US","og_type":"article","og_title":"AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference - Pharma Trend","og_description":"MENLO PARK, Calif.&#8211;(BUSINESS WIRE)&#8211;AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, Co-Founder, President and CEO will present at the SVB Securities Global Biopharma Conference. Details of the event is as follows: SVB Securities Global ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/an2-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-31T22:02:40+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230131005415\/en\/1694868\/21\/an2_therapeutics_logo_weba_%28003%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/an2-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/an2-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference","datePublished":"2023-01-31T22:02:40+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/an2-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/"},"wordCount":241,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/an2-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230131005415\/en\/1694868\/21\/an2_therapeutics_logo_weba_%28003%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/an2-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/","url":"https:\/\/pharma-trend.com\/en\/an2-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/","name":"AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/an2-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/an2-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230131005415\/en\/1694868\/21\/an2_therapeutics_logo_weba_%28003%29.jpg","datePublished":"2023-01-31T22:02:40+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/an2-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/an2-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/an2-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230131005415\/en\/1694868\/21\/an2_therapeutics_logo_weba_%28003%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230131005415\/en\/1694868\/21\/an2_therapeutics_logo_weba_%28003%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/an2-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53494","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53494"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53494\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53494"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53494"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53494"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}